Elects Thomas Pfisterer and Douglas Manion, MD, FRCP(C), to the Board of Directors SARASOTA, Fla., January 25, 2022 — Lakewood-Amedex Inc., a privately held, clinical stage pharmaceutical discovery and development company advancing a broad portfolio of first-in-class antimicrobial and antifungal therapeutics called Bisphosphocins®, today announced that two new...
Lakewood-Amedex Therapeutics Inc. today announced that Peter B. Corr, Ph.D., has been elected as Chairman of the Board of Directors of the company. Dr. Corr assumes the role from Steve Parkinson, who continues to serve as President and CEO....
Lakewood-Amedex Inc. today announced that the U.S. Patent and Trademark Office (USPTO) has issued a “Notice of Allowance” for two broad patent applications related to the Company’s broad-spectrum antimicrobial Nu-8 Bisphosphocin compound, titled “Antimicrobial Compounds, Compositions, and Uses Thereof....
LOS ANGELES, CA / ACCESSWIRE / November 29, 2018 / Lakewood-Amedex, a leading developer of novel anti-infective pharmaceuticals, today announced that it will be presenting at the 11th annual LD Micro Main Event on Thursday, December 6 at 11:00 AM PST / 2:00 PM EST. Steve Parkinson, CEO...
SARASOTA, Fla., February 8, 2018 - Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, today announced that it will present at the 2018 BIO CEO & Investor Conference, held February 12-13, 2018, in New York City. Steve Parkinson, President and CEO of Lakewood-Amedex, plans to present...
SARASOTA, Fla., December 4, 2017 - Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, today announced that it will be advancing a second Bisphosphocin drug candidate, Nu-8, into preclinical IND-enabling studies following pre-IND written communications with the U.S. Food and Drug Administration (FDA). Nu-8 will...
SARASOTA, Fla., Sept. 27, 2017 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, today announced it will present at the BioPharm America Conference top-line Phase 1/2a clinical data for its lead program, topically applied Nu-3 antimicrobial, to eliminate infection and promote wound healing in patients...
SARASOTA, Fla., Aug. 31, 2017 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that Neil J. Campbell, MA, MBA, and Leonard DeRoma, MBA, will be joining the company's Board of Directors. Mr. Campbell has over 25 years as a global C-level serial entrepreneur executive,...
SARASOTA, Fla., Aug. 22, 2017 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today the completion of patient treatment in the final cohort of the Company's Phase 1/2a clinical trial for its lead program, topically applied Bisphosphocin Nu-3 antimicrobial, for patients...
SARASOTA, Fla., April 4, 2017 /PRNewswire/ -- Lakewood-Amedex Inc., a clinical stage pharmaceutical company developing novel anti-infectives, announced today that it is advancing its second bisphosphocin candidate toward clinical development in 2017. The Company reported new in vitro data confirming the unique mechanism of action...